SynBioBeta Speaker
Zachary Gobst
Leapcure
CEO
Founder and CEO of Leapcure, the leader in patient engagement and recruitment for clinical trials. Leapcure’s equitable and empathetic service accelerates research while empowering patient advocacy. Hundreds of studies and millions of patients across more than 50 countries have used Leapcure to average 62% of study participation. Zach is also a lover of Tufte data visualization, podcasting with anyone, sleep, Fulham FC and Indiana University football (at least recently).
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Zachary
This Year
•
-
Human Health
Rewriting the Rules - Clinical Trial Reform in the Age of AI
AI-native drug discovery is accelerating molecule design, but clinical trials remain slow, expensive, and exclusionary. If we don’t modernize trial infrastructure, we create a bottleneck between computational breakthroughs and real-world patient impact. This breakout explores how to reform recruitment, eligibility, endpoints, biomarkers, and regulatory alignment to make U.S. trials more competitive and globally scalable.
Get a Ticket
Featuring
Zachary Gobst
Leapcure
CEO
Making clinical trials more equitable and accessible.
Jacob Becraft
Strand
CEO & Co-founder
MIT “mRNA programming language” inventor building programmable RNA medicines. Former Ron Weiss lab, interned with Bob langer
Jacob Glanville
Centivax
CEO
Building a universal antivenom
Una Ryan
Ulux
Founder and CEO
•
-
Human Health
Rewriting the Rules - Clinical Trial Reform in the Age of AI
AI-native drug discovery is accelerating molecule design, but clinical trials remain slow, expensive, and exclusionary. If we don’t modernize trial infrastructure, we create a bottleneck between computational breakthroughs and real-world patient impact. This breakout explores how to reform recruitment, eligibility, endpoints, biomarkers, and regulatory alignment to make U.S. trials more competitive and globally scalable.
Get a Ticket
Featuring
Zachary Gobst
Leapcure
CEO
Making clinical trials more equitable and accessible.
Jacob Becraft
Strand
CEO & Co-founder
MIT “mRNA programming language” inventor building programmable RNA medicines. Former Ron Weiss lab, interned with Bob langer
Jacob Glanville
Centivax
CEO
Building a universal antivenom
Una Ryan
Ulux
Founder and CEO
Session lineup still growing
Get a Ticket
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Get a Ticket
Featuring
Speaker Coming Soon
